Novartis And Stemline Try For Fast-Track EU Review

 
• By Neena Brizmohun

The European Medicines Agency is this week deciding whether it will fast track its review of orphan drugs that Novartis is developing for the treatment of Cushing's syndrome and Stemline Therapeutics is developing for the hematologic malignancy, BPDCN.

Binary code
Requests for fast track drug reviews in the EU are being considered this week • Source: Shutterstock

More from Product Reviews

More from Pink Sheet